Island Pharmaceuticals Limited (ASX:ILA)

Market Cap	125.76M +126.6%
Revenue (ttm)	282.66K +137.7%
Net Income	-9.84M
EPS	-0.04
Shares Out	295.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,266
Open	0.4250
Previous Close	0.4250
Day's Range	0.4250 - 0.4350
52-Week Range	0.2000 - 0.6300
Beta	0.12
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company’s lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ILA

Financial Performance

In fiscal year 2026, Island Pharmaceuticals's revenue was 282,657, an increase of 137.71% compared to the previous year's 118,910. Losses were -9.84 million, 151.1% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error